Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070928 · ClinicalTrials.gov registry record · Phase 2
Valerian to Improve Sleep in Patients With Parkinson's Disease
A Phase 2 study of Parkinson's Disease and Insomnia, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00070928: Completed Phase 2 study of Parkinson's Disease and Insomnia, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00070928 is a Phase 2 study of Parkinson's Disease and Insomnia that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 80 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070928, a Phase 2 study of Parkinson's Disease and Insomnia, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with Parkinson's disease (PD).
Conditions Studied
Interventions
- DRUG valerian
Study Locations (1)
Georgia
- Emory University Medical School/Wesley Woods Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00070928 record still lists
NCT00070928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which valerian is the first listed.
NCT00070928 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00070928 about?
NCT00070928 is a clinical study titled "Valerian to Improve Sleep in Patients With Parkinson's Disease". The purpose of this trial is to test the short-term effectiveness of valerian, a medicinal herb, to improve sleep in patients with Parkinson's disease (PD).
What is the current status of trial NCT00070928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2000-09. Estimated completion is 2006-06.
What conditions does trial NCT00070928 study?
This clinical trial studies the following conditions: Parkinson's Disease, Insomnia.
What interventions are being tested in trial NCT00070928?
The interventions under investigation include: valerian (DRUG).
Who is sponsoring clinical trial NCT00070928?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070928 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00070928's enrollment target sits among peer trials
80 63rd of 158 higher than 95 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia